Publications by authors named "Katja Kollewe"

Article Synopsis
  • Researchers have successfully applied spider silk fibers in nerve repair for the first time in humans, following previous successful sheep trials.
  • Four patients with nerve defects greater than 20 cm were treated using spider silk conduits within their veins, showing promising results over a follow-up period of 2 to 10 years.
  • All patients experienced primary healing without adverse effects, and many regained significant sensory and motor function, indicating spider silk conduits could be a viable option for complex nerve repairs.
View Article and Find Full Text PDF
Article Synopsis
  • A large-scale genome-wide association study (GWAS) was conducted with over 6000 participants to investigate genetic risk factors for isolated dystonia, aiming to improve upon earlier studies that found no significant genetic links.
  • The study included 4303 dystonia patients and 2362 healthy controls, analyzing various factors like age of onset and affected body areas, but ultimately failed to identify any common genetic variants associated with dystonia.
  • The findings suggest that isolated dystonia may not be influenced by common genetic variations, highlighting the need for more extensive studies like whole-genome sequencing to uncover potential genetic contributions.
View Article and Find Full Text PDF

The different peaks of somatosensory-evoked potentials (SEP) originate from a variety of anatomical sites in the central nervous system. The origin of the median nerve subcortical N18 SEP has been studied under various conditions, but the exact site of its generation is still unclear. While it has been claimed to be located in the thalamic region, other studies indicated its possible origin below the pontomedullary junction.

View Article and Find Full Text PDF

Background: Pathogenic variants in several genes have been linked to genetic forms of isolated or combined dystonia. The phenotypic and genetic spectrum and the frequency of pathogenic variants in these genes have not yet been fully elucidated, neither in patients with dystonia nor with other, sometimes co-occurring movement disorders such as Parkinson's disease (PD).

Objectives: To screen >2000 patients with dystonia or PD for rare variants in known dystonia-causing genes.

View Article and Find Full Text PDF
Article Synopsis
  • * A study comparing 26 PGAD patients with 26 healthy controls revealed that PGAD symptoms were often described as persistent tingling or prickling sensations, primarily in the clitoris, with various triggers and relief strategies identified.
  • * The PGAD group exhibited higher rates of sexual dysfunctions, depression, and certain anxiety disorders compared to controls, but showed no significant differences in factors like childhood trauma or neurophysiological evaluations of the pudendal nerve.
View Article and Find Full Text PDF

Introduction: Dystonia is a movement disorder of variable etiology and clinical presentation and is accompanied by tremor in about 50% of cases. Monogenic causes in dystonia are rare, but also in the group of non-monogenic dystonias 10-30% of patients report a family history of dystonia. This points to a number of patients currently classified as idiopathic that have at least in part an underlying genetic contribution.

View Article and Find Full Text PDF

Background: Chronic migraine (CM) is associated with substantial economic burden. Real-world data suggests that onabotulinumtoxinA treatment for CM reduces healthcare resource utilisation (HRU) and related costs.

Methods: REPOSE was a 2-year prospective, multicentre, non-interventional, observational study to describe the real-world use of onabotulinumtoxinA in adult patients with CM.

View Article and Find Full Text PDF

An inherent challenge to clinical trials that aim to test the efficacy of experimental therapeutics for patients with amyotrophic lateral sclerosis (ALS) is the relative rarity of the disease. A promising solution to this problem is a multi-center approach that ideally includes sites distributed across a broad geographic area. In support of such an approach, the European E-RARE program and the United States National Institutes of Health (NIH) partnered to support the investigator-initiated ROCK-ALS trial (Eudra-CT-Nr.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the link between botulinum toxin (BT) therapy and dysphagia in cervical dystonia (CD) patients over a year, focusing on the frequency and duration of swallowing difficulties.
  • Out of 75 patients analyzed, about 20% experienced dysphagia, but it occurred infrequently and was not tied to any significant functional impairments.
  • It was found that factors like patient age, gender, and BT dosage did not influence dysphagia occurrence, and attempts to prevent it using ultrasound guidance were unsuccessful, prompting the need for further research.
View Article and Find Full Text PDF

Background: The antisense-oligonucleotide (ASO) nusinersen has recently been approved as the first genetically modifying therapy for 5q-associated spinal muscular atrophy (SMA) based on randomized sham-controlled trials in infants and children. The efficacy in adults with long disease history and advanced disease status is still widely unknown; the same applies to specific expectations of adult SMA patients and to what extent they are met and may impact outcome measures.

Methods: In a longitudinal monocentric study in adult patients with SMA types 2-4, the Stanford Expectations of Treatment Scale (SETS) was assessed prior to and during nusinersen treatment.

View Article and Find Full Text PDF
Article Synopsis
  • There is currently no evidence-based treatment for fatigue in ALS, but dyspnea may contribute to fatigue levels in patients with this condition.
  • A study involving 101 dyspneic ALS patients found that they reported significantly higher fatigue scores compared to those without dyspnea, and dyspnea explained a notable portion of fatigue variance.
  • The findings suggest a strong link between dyspnea-related distress and fatigue, highlighting the need for better treatment options and symptom management strategies for ALS patients beyond just noninvasive ventilation.
View Article and Find Full Text PDF

The objective of this study is to discover whether incobotulinumtoxinA (inco) can reduce relative hypersalivation in patients with amyotrophic lateral sclerosis (ALS). 14 patients with ALS (8 males and 6 females, age 55.4 ± 16.

View Article and Find Full Text PDF

Based on epidemiological data it was believed that botulinumtoxin type D (BT-D) may not block human cholinergic synapses. We wanted to investigate BT-D's effect on the autonomic cholinergic synapse in humans. For this, we compared in four volunteers intraindividually the hypohidrotic effect of intradermal BT-D and BT-A in Minor's iodine starch sweat test.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates Botulinum neurotoxin serotype D (BoNT/D) as a potential alternative treatment for patients who do not respond to the widely used BoNT/A and B due to the formation of neutralizing antibodies.
  • - BoNT/D was produced in E. coli and tested for its efficacy in both mouse tissues and human volunteers, showing that while it's less potent, it can produce similar effects with a higher dosage and shorter action duration.
  • - The findings suggest BoNT/D could be a viable option for patients who don't respond to other serotypes, despite its lower effectiveness compared to approved treatments.
View Article and Find Full Text PDF

There is increasing evidence for hippocampal involvement in Amyotrophic Lateral Sclerosis (ALS). Recent neuroimaging studies have been focused on disease-related hippocampal volume alterations while changes in hippocampal shape have been investigated less frequently. Here, we aimed to characterize the patterns of hippocampal degeneration using both an automatic and manual volumetric and surface-based approach in a group of 31 patients with ALS and 29 healthy controls.

View Article and Find Full Text PDF

Purpose To investigate the whole-brain landscape of iron-related abnormalities in amyotrophic lateral sclerosis (ALS) by using the in vivo MRI technique of quantitative susceptibility mapping (QSM). Materials and Methods For this prospective study, 28 patients with ALS (mean age, 61 years; age range, 43-77 years; 18 men [mean age, 61 years; range, 43-77 years] and 10 women [mean age, 61 years; range, 47-74 years]) recruited between January 17, 2014, and September 4, 2015, and 39 matched control subjects (mean age, 61 years; age range, 39-77 years; 24 men [mean age, 62 years; range, 39-77 years] and 15 women [mean age, 59 years; range, 39-73 years]) were examined by using structural and susceptibility 3.0-T MRI techniques.

View Article and Find Full Text PDF

Objective: Spinal and bulbar muscular atrophy (SBMA) is caused by an abnormal expansion of the CAG repeat in the androgen receptor gene. This study aimed to systematically phenotype a German SBMA cohort (n = 80) based on laboratory markers for neuromuscular, metabolic, and endocrine status, and thus provide a basis for the selection of biomarkers for future therapeutic trials.

Methods: We assessed a panel of 28 laboratory parameters.

View Article and Find Full Text PDF

Botulinum toxin is now used for numerous indications including dystonias, spasticity, cerebral palsy, hyperhidrosis, cosmetics and chronic migraine. It has to be injected into its target tissues thus causing injection site pain. We wanted to compare the efficacy of various analgesic interventions suggested for reduction of injection site pain.

View Article and Find Full Text PDF

Introduction: We aimed to investigate whether sonographic peripheral cross-sectional nerve area (CSA) and progranulin (PGRN), a neuritic growth factor, are related to each other and whether they interact to predict clinical and paraclinical measures in amyotrophic lateral sclerosis (ALS).

Methods: We included 55 ALS patients who had forearm median and ulnar nerve CSA, cerebrospinal fluid (CSF) PGRN, and serum PGRN measures available. CSF PGRN was normalized against the CSF / serum albumin ratio (Q ).

View Article and Find Full Text PDF
Article Synopsis
  • * The FDA approved onabotulinumtoxinA (Botox) in 2010 for preventing CM, and it has been shown to reduce both the frequency and intensity of headaches.
  • * The review covers the history and current clinical evidence supporting the use of onabotulinumtoxinA in managing chronic migraines.
View Article and Find Full Text PDF

Objectives: Primary lateral sclerosis (PLS) is commonly considered as a motor neuron disease (MND) variant which almost exclusively affects upper motor neurons (UMN). There is still no consensus whether PLS should be regarded as an independent disease entity separate from amyotrophic lateral sclerosis (ALS) or as a comparatively slowly progressive variant of ALS. Given these different views, clinical diagnosis of PLS is a challenge.

View Article and Find Full Text PDF

Purpose: Aim of the present study was to investigate potential impairment of non-motor areas in amyotrophic lateral sclerosis (ALS) using near-infrared spectroscopy (NIRS) and diffusion tensor imaging (DTI). In particular, we evaluated whether homotopic resting-state functional connectivity (rs-FC) of non-motor associated cortical areas correlates with clinical parameters and disease-specific degeneration of the corpus callosum (CC) in ALS.

Material And Methods: Interhemispheric homotopic rs-FC was assessed in 31 patients and 30 healthy controls (HCs) for 8 cortical sites, from prefrontal to occipital cortex, using NIRS.

View Article and Find Full Text PDF

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that affects upper and lower motor neurons. Observational and intervention studies can be tracked using clinical measures such as the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) but for a complete understanding of disease progression, objective in vivo biomarkers of both central and peripheral motor pathway pathology are highly desirable. The aim of this study was to determine the utility of structural and diffusion imaging as central nervous system biomarkers compared to the standard clinical measure, ALSFRS-R, to track longitudinal evolution using three time-point measurements.

View Article and Find Full Text PDF

Botulinum toxin was shown to be effective in treatment of chronic migraine. We wanted to explore its efficacy and tolerability in chronic application under real-life conditions. For this, 27 consecutive patients (age 45.

View Article and Find Full Text PDF

The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) has been developed to assess cognition and behaviour in patients with amyotrophic lateral sclerosis (ALS). Cognitive impairments of ALS-specific and ALS-non-specific functions can be determined using cut-off scores based on performance of healthy subjects. However, detailed analyses show that older healthy subjects perform worse than younger ones, whereas highly-educated individuals perform better than those with lower education levels.

View Article and Find Full Text PDF